AstraZeneca on Tuesday announced that its AKT inhibitor Truqap, when used in combination with paclitaxel, failed to meet its primary efficacy endpoint in the Phase III CAPItello-290 study in patients with metastatic triple-negative breast cancer.
Tag Archive for: capivasertib
The company said its experimental drug capivasertib was able to help patients with an advanced form of breast cancer live longer, when combined with the drugmaker’s older cancer treatment Faslodex regardless of biomarker status.